Provided by Tiger Trade Technology Pte. Ltd.

BriaCell Therapeutics Corp.

3.92
-0.2100-5.08%
Post-market: 3.990.0695+1.77%19:34 EST
Volume:146.19K
Turnover:580.65K
Market Cap:28.42M
PE:-0.12
High:4.12
Open:4.08
Low:3.91
Close:4.13
52wk High:98.20
52wk Low:3.67
Shares:7.25M
Float Shares:6.48M
Volume Ratio:0.78
T/O Rate:2.26%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-33.7856
EPS(LYR):-62.1862
ROE:-444.07%
ROA:-161.64%
PB:2.85
PE(LYR):-0.06

Loading ...

BriaCell Restructures Soluble CD80 Program via BriaPro Deal

TIPRANKS
·
Yesterday

BriaPro to purchase BriaCell’s license to develop, commercialize sCD80

TIPRANKS
·
Feb 19

BriaCell Therapeutics' Phase 3 Breast Cancer Treatment Trial Gets Fifth DSMB Recommendation to Continue

MT Newswires Live
·
Feb 17

BriaCell says patient images show regression, resolution of metastsized tumors

TIPRANKS
·
Jan 28

BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients

GlobeNewswire
·
Jan 27

BriaCell Therapeutics Completes $30 Million Public Offering

TIPRANKS
·
Jan 16

Crude Oil Gains Over 1%; US Retail Sales Rise 0.6% In November

Benzinga
·
Jan 15

US-Listed Shares of Briacell Therapeutics Tumble 55% After Co Prices $30 Mln Public Offering

THOMSON REUTERS
·
Jan 14

Top Premarket Decliners

MT Newswires Live
·
Jan 14

BriaCell Therapeutics Prices $30 Million Public Offering of Stock, Warrants

MT Newswires Live
·
Jan 14

BriaCell Therapeutics Announces Pricing of $30 million Public Offering

GlobeNewswire
·
Jan 14

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:51 AM

Reuters
·
Jan 13

BriaCell Therapeutics trading halted, volatility trading pause

TIPRANKS
·
Jan 13

BriaCell reports sustained complete resolution of lung metastasis in Bria-OTS

TIPRANKS
·
Jan 13

“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine

GlobeNewswire
·
Dec 18, 2025

BriaCell’s Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout

GlobeNewswire
·
Dec 09, 2025

BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025

GlobeNewswire
·
Dec 02, 2025

BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025

GlobeNewswire
·
Nov 25, 2025

BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics

GlobeNewswire
·
Nov 20, 2025

BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025

GlobeNewswire
·
Nov 18, 2025